FDA Brief

Warning letters Drugs

FDA warning letter to

Everymarket Inc.

High riskIssued Aug 27, 2024Posted Sep 3, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Everymarket Inc. that its website sells two unapproved drugs, one with hidden dexamethasone and chlorpheniramine.

What happened

In July 2024, FDA reviewed Everymarket's website at https://www.everymarket.com/ and found it offering Vail-Bon Jie Yang Wan and Ossos-Sans for sale in the United States. FDA obtained samples and labeling of Vail-Bon Jie Yang Wan, and laboratory analysis found undeclared dexamethasone and chlorpheniramine. FDA also cited a prior analysis showing Ossos-Sans contained undeclared diclofenac and methocarbamol, though it had not sampled that product from the company's inventory to date.

What FDA found

  1. FDA says Vail-Bon Jie Yang Wan and Ossos-Sans are unapproved new drugs sold without FDA-approved applications.

    sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. FDA says Vail-Bon Jie Yang Wan's labeling is false or misleading because it does not disclose dexamethasone and chlorpheniramine.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  3. FDA says the labeling claims for Vail-Bon Jie Yang Wan and Ossos-Sans show they are intended to treat diseases or affect body function, making them drugs.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  4. FDA says the products are not generally recognized as safe and effective for their labeled uses, so they are new drugs.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  5. FDA says the label's failure to reveal material facts about hidden drug ingredients makes Vail-Bon Jie Yang Wan misbranded.

    section 201(n) of the FD&C Act, 21 U.S.C. 321(n)

What FDA wants

FDA asks Everymarket to notify FDA in writing within 15 working days of receipt of the specific steps taken to correct the violations and prevent recurrence, with copies of related documentation. If the company believes the products are not in violation, FDA asks for its reasoning and supporting information.

Who should pay attention

  • online marketplaces selling imported drug products
  • retailers and distributors of herbal or joint products
  • consumers using arthritis or skin-itch products from online sellers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  4. C & A Naturistics

    C & A Naturistics sold unapproved new drugs online, including AK Forte with hidden acetaminophen and diclofenac.

    High risk